HAE · Haemonetics Corporation

Current Thesis

Haemonetics’ CSL agreement supports a plasma-recovery thesis that requires a quantified revenue contribution and transition timetable at the November 2026 results call; a weekly close below $91 invalidates the price structure supporting it.

The material change since September 6 is Citi’s reversal: on 2026-09-17, Joanne Wuensch upgraded Haemonetics from Neutral and raised the firm’s target to $123 from $92. Citi’s earlier downside framing can no longer be presented as its current view. The supplied adjusted market record puts the 2026-09-18 close at $108.40, versus $102.92 on 2026-09-04. Benzinga’s analyst-action record documents the upgrade.

The interpretation is that the narrative is maturing — Raymond James’ 2026-09-03 target increase and Citi’s 2026-09-17 upgrade extend an established analyst repricing, while company quantification remains outstanding. The 2026-08-18 disclosure left the scope and timing of CSL center transitions undetermined and reserved the financial-impact update for November. Analyst endorsement strengthens attention to the case; it does not establish customer adoption. Haemonetics’ August disclosure separates those questions.

Bullish and bearish views on Haemonetics Corporation

The model's bull view on Haemonetics Corporation (HAE), in brief: Plasma growth precedes CSL contribution. The bear view: The contract guarantees no volume. Haemonetics’ 2026-08-18 disclosure describes the CSL agreement as non-exclusive and without minimum purchase commitments. A signed agreement therefore does not establish a revenue floor. The company disclosure states those limitations. CSL… Both cases follow in full.

Bull Case

• Plasma growth precedes CSL contribution. Haemonetics’ 2026-08-06 results reported first-quarter fiscal 2027 Plasma revenue of $155.5 million and organic growth of 8.2%. That operating evidence predates the agreement signed on 2026-08-14.
• Interventional Technologies returned to growth. The 2026-08-06 release reported revenue of $59.9 million and organic growth of 2.8%, following a 10.3% organic decline in the preceding quarter. This establishes an improvement, although the sample is too small to establish a durable recovery.
• The operating plan already improved. On 2026-08-06, management raised fiscal 2027 organic revenue-growth guidance to 4–7%. The 2026-08-18 CSL disclosure left that guidance unchanged, placing the new agreement outside the quantified forecast.
• A previously cautious analyst reversed. Citi’s 2026-09-17 upgrade and $123 target followed Raymond James’ 2026-09-03 increase to $125. These are attributed analyst forecasts, not company revenue commitments. Benzinga’s dated actions show the change.

Bear Case

• The contract guarantees no volume. Haemonetics’ 2026-08-18 disclosure describes the CSL agreement as non-exclusive and without minimum purchase commitments. A signed agreement therefore does not establish a revenue floor. The company disclosure states those limitations.
• CSL already has installed equipment. Terumo BCT and CSL Plasma announced completion of the nationwide Rika rollout on 2025-09-26. That disclosed installation makes the pace and scope of any subsequent Haemonetics transition central to the revenue case.
• Margin improvement remains incomplete. The 2026-08-06 results and call reported a first-quarter adjusted operating margin of 16.9%, up 10 basis points year over year, against fiscal 2027 guidance for expansion of 50–100 basis points. A second-quarter contraction accompanied by reduced annual margin guidance would undermine the operating-recovery component.

Setup & Price Structure

The supplied adjusted daily-bar record shows a 2026-09-18 close of $108.40, 0.4% below the recorded 52-week high of $108.80. The same record shows a three-month price increase of 49.5% and a 14-day relative strength index (RSI) of 66.8. These measure appreciation and momentum; they do not measure ownership concentration.

The recovery toward the recorded high supersedes the September 6 note’s description of price failing to follow analyst optimism. A weekly close above $108.80 would establish a closing breakout through that reference high; a weekly close below $91 would invalidate the retained August-gap structure. The latter threshold sits near the documented 2026-08-14 pre-disclosure close of $90.80.

Coverage has clustered around target revisions, including Raymond James on 2026-09-03 and Citi on 2026-09-17. The available evidence does not establish retail crowding, fund inflows or distance above a rising moving average. Conviction remains moderate because the measured operating improvement and price recovery coexist with the unquantified implementation described on 2026-08-18.

Catalyst Calendar (next 30 days)

• 2026-09-22 — Barrington Research conference. Haemonetics lists participation in the virtual fall investment conference. Any disclosed CSL transition details would narrow the implementation uncertainty; an appearance without such details would leave it unresolved. Company event calendar.
• 2026-09-24 — Bernstein healthcare forum. Haemonetics lists participation in the New York event. The relevant evidence would be company commentary on implementation timing or operating progress; attendance alone supplies neither. Company event calendar.
• ~2026-11-05, estimated — Second-quarter fiscal 2027 results. This falls beyond the next 30 days but is the thesis-defining event. November is the company’s stated window for discussing CSL’s financial impact; November 5 remains an estimated earnings date, not a company-confirmed appointment. Company disclosure and MarketBeat’s earnings-date estimate.

What Would Change Our Mind

Loss of the August disclosure gap would break the market-confirmation component: a weekly close below $91 is the observable threshold, near the 2026-08-14 close of $90.80. The threshold remains unchanged despite the subsequent recovery toward $108.80.

The fundamental case succeeds if the November 2026 call supplies a quantified positive fiscal 2027 CSL revenue contribution and a center-transition timetable before that price threshold is breached. A call that supplies neither would invalidate the near-term monetization thesis. An unchanged 4–7% organic-growth range alone would not establish failure, because its breadth could accommodate a contribution.

Correlation Notes

This remains a single-name recovery case. The dated evidence concerns Haemonetics’ 2026-08-06 segment results, its 2026-08-18 CSL disclosure and Citi’s 2026-09-17 upgrade; no matched peer-return series establishes a broader medical-technology move.

Terumo and CSL disclosures are relevant competitive evidence because their 2025-09-26 announcement documented the installed Rika network. That commercial relationship does not establish a stock-price correlation. No numerical correlation claim is supported by the available sample.